Skip to main content
NeopharmCO.,LTD. logo

NeopharmCO.,LTD. — Investor Relations & Filings

Ticker · 092730 ISIN · KR7092730001 KO Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2021-11-12 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 092730

About NeopharmCO.,LTD.

https://neopharm.co.kr

Neopharm is a science-based company specializing in the development, manufacturing, and sale of dermatological skincare and cosmetic products. A pioneer in skin barrier research, the company focuses on restoring skin homeostasis. Its core innovation is the proprietary Multi-Lamellar Emulsion (MLE) technology, which mimics the natural lipid structure of the skin to repair and strengthen its protective functions. The company's primary product lines, including the flagship brand Atopalm, are specifically formulated for sensitive, dry, and compromised skin. These non-steroid solutions are grounded in dermatological science to address various skin concerns.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for NeoPharm, covering the period from January 1, 2021, to September 30, 2021. It contains detailed financial information, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-11-12 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (잠정실적) for Neopharm, detailing quarterly financial performance (revenue, operating profit, net income) for the period ending 2021-09-30. It provides key financial highlights and comparisons to previous periods, which is characteristic of an Earnings Release (ER). It is not a full report, but rather a summary announcement of financial results. Q3 2021
2021-11-05 Korean
기타경영사항(특허권취득)(자율공시)(피지의 과다분비 억제용 조성물)
Regulatory Filings Classification · 100% confidence The document is a short, voluntary disclosure (자율공시) regarding the acquisition of a patent by Neopharm. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a regulatory disclosure of a corporate event (patent acquisition) that does not fall into the other specific categories, it is classified as a general regulatory filing.
2021-11-03 Korean
기타경영사항(특허권취득)(자율공시)(항염용 조성물)
Regulatory Filings Classification · 100% confidence The document is a short, voluntary disclosure (자율공시) regarding the acquisition of a patent by Neopharm. It does not fit into financial reporting categories like 10-K or IR, nor does it relate to dividends, management changes, or share transactions. As it is a specific regulatory disclosure regarding corporate operations (patent acquisition) that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2021-11-03 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'NeoPharm' for the period ending June 30, 2021. It contains detailed financial information, business operations, management discussions, and corporate governance data. According to the provided definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) that contains actual financial statements and analysis is classified as an Interim/Quarterly Report (IR). H1 2021
2021-08-13 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Neopharm, detailing quarterly financial highlights such as revenue, operating profit, and net income. It is a short, structured announcement of financial results rather than a full comprehensive report, fitting the definition of an Earnings Release (ER). Q2 2021
2021-08-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.